Lepu Biopharma Co., Ltd. (HKG:2157)
Hong Kong
· Delayed Price · Currency is HKD 5.32
-0.08 (-1.48%)
Apr 29, 2026, 4:08 PM HKT
Lepu Biopharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 934.87 | 367.79 | 225.35 | 15.57 | - | Upgrade
|
| Revenue Growth (YoY) | 154.18% | 63.21% | 1347.16% | - | - | Upgrade
|
| Cost of Revenue | 89.59 | 74.82 | 28.28 | 2.01 | - | Upgrade
|
| Gross Profit | 845.28 | 292.97 | 197.08 | 13.57 | - | Upgrade
|
| Selling, General & Admin | 354.46 | 237.89 | 129.95 | 140.58 | 156.24 | Upgrade
|
| Research & Development | 400.71 | 437.7 | 458.07 | 524.29 | 791.21 | Upgrade
|
| Other Operating Expenses | 64.09 | 13.23 | -0.38 | -8.85 | -3.77 | Upgrade
|
| Operating Expenses | 819.25 | 688.82 | 587.65 | 656.02 | 943.68 | Upgrade
|
| Operating Income | 26.02 | -395.85 | -390.57 | -642.45 | -943.68 | Upgrade
|
| Interest Expense | -29.31 | -21.65 | -14.68 | -7.47 | -2.7 | Upgrade
|
| Interest & Investment Income | 5.28 | 4.67 | 8.18 | 8.35 | 9.1 | Upgrade
|
| Earnings From Equity Investments | -7.51 | -16.44 | -27.34 | -32.23 | -17.7 | Upgrade
|
| Currency Exchange Gain (Loss) | 7.05 | 1.33 | 0.21 | 37.75 | -2.41 | Upgrade
|
| Other Non Operating Income (Expenses) | -31.36 | 3.74 | 173.64 | -64 | -76.86 | Upgrade
|
| EBT Excluding Unusual Items | -29.83 | -424.2 | -250.56 | -700.05 | -1,034 | Upgrade
|
| Gain (Loss) on Sale of Investments | 289.55 | - | 220.26 | - | 5.37 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.91 | 0.01 | - | 0.61 | - | Upgrade
|
| Pretax Income | 260.64 | -424.19 | -30.3 | -699.44 | -1,029 | Upgrade
|
| Income Tax Expense | 1.75 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | 258.89 | -424.19 | -30.3 | -699.44 | -1,029 | Upgrade
|
| Minority Interest in Earnings | 2.48 | 12.82 | 8.21 | 10.39 | 17.87 | Upgrade
|
| Net Income | 261.36 | -411.38 | -22.1 | -689.05 | -1,011 | Upgrade
|
| Net Income to Common | 261.36 | -411.38 | -22.1 | -689.05 | -1,011 | Upgrade
|
| Shares Outstanding (Basic) | 1,755 | 1,690 | 1,659 | 1,641 | 1,520 | Upgrade
|
| Shares Outstanding (Diluted) | 1,755 | 1,690 | 1,659 | 1,641 | 1,520 | Upgrade
|
| Shares Change (YoY) | 3.82% | 1.87% | 1.14% | 7.92% | 33.97% | Upgrade
|
| EPS (Basic) | 0.15 | -0.24 | -0.01 | -0.42 | -0.66 | Upgrade
|
| EPS (Diluted) | 0.15 | -0.24 | -0.01 | -0.42 | -0.66 | Upgrade
|
| Free Cash Flow | - | -229.31 | -278.84 | -591.38 | -835.12 | Upgrade
|
| Free Cash Flow Per Share | - | -0.14 | -0.17 | -0.36 | -0.55 | Upgrade
|
| Gross Margin | 90.42% | 79.66% | 87.45% | 87.12% | - | Upgrade
|
| Operating Margin | 2.78% | -107.63% | -173.32% | -4125.67% | - | Upgrade
|
| Profit Margin | 27.96% | -111.85% | -9.80% | -4424.94% | - | Upgrade
|
| Free Cash Flow Margin | - | -62.35% | -123.73% | -3797.71% | - | Upgrade
|
| EBITDA | 108.19 | -313.69 | -306.66 | -564.63 | -866.49 | Upgrade
|
| EBITDA Margin | 11.57% | -85.29% | -136.08% | - | - | Upgrade
|
| D&A For EBITDA | 82.16 | 82.16 | 83.91 | 77.82 | 77.18 | Upgrade
|
| EBIT | 26.02 | -395.85 | -390.57 | -642.45 | -943.68 | Upgrade
|
| EBIT Margin | 2.78% | -107.63% | -173.31% | - | - | Upgrade
|
| Effective Tax Rate | 0.67% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.